Litigation Details for Amgen Inc. v. Sandoz Inc. (Fed. Cir. 2021)

« Back to Dashboard

Amgen Inc. v. Sandoz Inc. (Fed. Cir. 2021)

Docket		Date Filed	2021-11-12
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	10,092,541; 6,962,940; 7,208,516; 7,427,638; 7,659,302; 7,893,101; 8,455,536
Link to Docket	External link to docket

Details for Amgen Inc. v. Sandoz Inc. (Fed. Cir. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-11-12				External link to document
2021-11-11	27		’541 patent U.S. Patent No. 10,092,541 (Appx10619-10640) ’638 patent U.S. Patent No. 7,…, U.S. Patent No. 8,455,536 (the ` 536 Patent"), U.S. Patent No. 10,092,541 (the "' 541…claims 2, 19, and 21 of U.S. Patent No. 10,092,541 (the "' 541 Patent") ( … States Patent (10) Patent No.: US 10,092,541 B2 …0013 Certified Copy of U.S. Patent No. 10,092,541 ....................... Appx10619 Case:	External link to document

Amgen Inc. v. Sandoz Inc. 22-1147: Sensipar Patent Litigation Summary and Analysis

Last updated: August 8, 2026

Amgen lost its Federal Circuit appeal in Amgen Inc. v. Sandoz Inc., No. 22-1147. The court affirmed that Amgen's U.S. Patent No. 9,375,405, directed to cinacalcet treatment methods for secondary hyperparathyroidism in dialysis patients, was invalid for obviousness. The decision removed the principal patent barrier asserted against Sandoz's generic Sensipar product and materially reduced Amgen's remaining U.S. exclusivity protection for cinacalcet tablets.[1]

The case concerned generic cinacalcet hydrochloride, marketed by Amgen as Sensipar. It was an ANDA patent dispute under the Hatch-Waxman Act, not a biologic patent case. Biosimilar risk, BPCIA procedures, and biologic exclusivity were not central to the dispute.

What was the dispute in Amgen v. Sandoz, No. 22-1147?

The dispute involved whether Sandoz's proposed generic cinacalcet product infringed valid claims of U.S. Patent No. 9,375,405.

Amgen asserted the '405 patent against Sandoz after Sandoz filed an abbreviated new drug application containing a Paragraph IV certification. Sandoz argued that the asserted claims were invalid, including on obviousness grounds. The U.S. District Court for the District of Delaware ruled for Sandoz after a bench trial. Amgen appealed to the U.S. Court of Appeals for the Federal Circuit.

The Federal Circuit affirmed the district court's judgment. The appellate decision left the invalidity ruling intact and did not create a new infringement standard or alter Hatch-Waxman Paragraph IV law.

Case profile

Item	Detail
Case	Amgen Inc. v. Sandoz Inc.
Federal Circuit docket	No. 22-1147
Court	U.S. Court of Appeals for the Federal Circuit
Product	Sensipar, cinacalcet hydrochloride
Proposed generic	Sandoz cinacalcet tablets
Patent at issue	U.S. Patent No. 9,375,405
Patent owner	Amgen Inc.
District court	U.S. District Court for the District of Delaware
Primary issue	Obviousness of method-of-treatment claims
Federal Circuit result	Affirmed judgment against Amgen
Decision year	2023
FDA pathway	ANDA under the Hatch-Waxman Act

What patent protected Sensipar and what did the Federal Circuit decide?

The '405 patent claimed methods for treating secondary hyperparathyroidism in patients with chronic kidney disease who were receiving dialysis. The claims generally required administering cinacalcet and titrating treatment based on the patient's response, with the objective of reducing parathyroid hormone levels.

The Federal Circuit agreed that the asserted claims would have been obvious to a person of ordinary skill in the art. The court accepted the district court's analysis that the relevant prior art disclosed the clinical use of cinacalcet, treatment of secondary hyperparathyroidism, dialysis populations, and dose-adjustment concepts.

The court's decision focused on the familiar obviousness framework under Graham v. John Deere and KSR v. Teleflex:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the art.
4. Objective indicia of nonobviousness, including commercial success and unexpected results.

The appellate court concluded that the district court properly found a motivation to combine the relevant prior-art teachings and a reasonable expectation of success. Amgen's evidence of commercial success did not overcome the obviousness showing because the district court did not find the required nexus between the commercial success of Sensipar and the specific claimed features.

What was the patent's technical scope?

The patent covered a clinical treatment regimen rather than the basic discovery or composition of cinacalcet. The asserted subject matter related to:

• Treatment of secondary hyperparathyroidism.
• Patients with chronic kidney disease.
• Patients receiving dialysis.
• Administration of cinacalcet.
• Dose initiation and titration.
• Reduction or control of parathyroid hormone levels.

This distinction mattered commercially. A method-of-use patent can block an ANDA product only when the proposed labeling and conduct support infringement. It does not provide the same protection as a broad composition-of-matter patent covering the active ingredient itself.

When did Sensipar lose patent protection?

The Federal Circuit decision did not independently establish a new expiration date for all Sensipar-related patents. It invalidated the asserted '405 patent, eliminating that patent as an enforceable barrier regardless of its scheduled expiration date.

The commercial exclusivity analysis must distinguish among:

Exclusivity type	Sensipar status
New chemical entity exclusivity	Expired
Basic active-ingredient exclusivity	Expired
Method-of-use patent protection	The '405 patent was held invalid
Orange Book-listed patents	Must be assessed patent by patent
Pediatric exclusivity	Any applicable period is separate from patent validity
Generic approval exclusivity	Depends on ANDA certification and FDA approval status
Biologic exclusivity	Not applicable

Cinacalcet was first approved by the FDA in 2004. Sensipar's principal commercial protection therefore depended heavily on follow-on patents, regulatory exclusivity, and litigation strategy rather than continuing new-chemical-entity exclusivity.[2]

Did the case end all Sensipar patent protection?

No. The decision addressed the patent claims litigated in the appeal. It did not automatically invalidate every patent associated with Sensipar, every formulation patent, or every patent listed in the FDA's Orange Book.

The practical effect was narrower but significant: Amgen could no longer rely on the '405 patent to prevent Sandoz's proposed generic cinacalcet product from entering the market.

How did the Paragraph IV challenge affect generic entry?

Sandoz's ANDA Paragraph IV certification triggered the Hatch-Waxman litigation process. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Amgen's timely infringement action imposed a statutory stay on FDA approval of Sandoz's ANDA for up to 30 months, subject to statutory exceptions and court developments. The litigation then determined whether the patent could continue to block approval or commercial launch.

The Federal Circuit's affirmance strengthened Sandoz's position in three ways:

• The asserted patent could no longer support an injunction.
• The invalidity ruling became the operative judgment in the case.
• Sandoz's generic launch risk was reduced, subject to FDA approval, other listed patents, regulatory requirements, and any separate commercial agreement.

The decision did not itself order FDA approval. FDA approval remains a regulatory action governed by the ANDA record, applicable patent certifications, labeling, manufacturing, and bioequivalence requirements.

What was the FDA and Orange Book status of Sensipar?

Sensipar is an FDA-approved small-molecule drug containing cinacalcet hydrochloride. It is approved for specified hyperparathyroidism indications and for hypercalcemia associated with parathyroid carcinoma in applicable patient populations.

The product is subject to the Hatch-Waxman framework and Orange Book patent listings. Unlike a biologic approved under a biologics license application, Sensipar does not involve the Purple Book or the BPCIA biosimilar pathway.

The litigation analysis must separate three FDA questions:

Was Sandoz seeking approval through the ANDA pathway?

Yes. The dispute was based on Sandoz's ANDA for generic cinacalcet tablets.

Did the Federal Circuit approve Sandoz's product?

No. The court decided patent validity. It did not grant FDA approval or determine whether Sandoz satisfied all ANDA requirements.

Did invalidity of the '405 patent remove all FDA barriers?

Not necessarily. The effect depends on the complete Orange Book listing, the status of other patents, any applicable exclusivity, FDA review, and the scope of Sandoz's certifications.

What patent litigation affected generic cinacalcet entry?

The litigation followed the standard sequence for an ANDA Paragraph IV dispute:

Stage	Event
ANDA filing	Sandoz submitted a generic cinacalcet application with a Paragraph IV certification
Notice	Amgen received notice of Sandoz's challenge
District court litigation	Amgen asserted the '405 patent
Trial	The District of Delaware considered validity and related issues
District court judgment	The patent claims were held invalid
Appeal	Amgen appealed to the Federal Circuit
Federal Circuit decision	The judgment against Amgen was affirmed
Commercial effect	The asserted patent no longer blocked Sandoz on the basis litigated

The opinion did not create a broad rule that all dose-adjustment or treatment-method patents are obvious. Its holding was tied to the evidence and claim limitations in the '405 patent.

How strong was Amgen's patent estate for cinacalcet?

Amgen's estate was commercially important but structurally vulnerable because the litigated claims were method-of-use claims covering a known drug used in a known disease setting.

Strengths

• Sensipar had a substantial established market.
• The patent claims were directed to a clinically relevant dialysis population.
• Dose titration and treatment response can create meaningful infringement issues when generic labeling tracks the branded indication.
• ANDA litigation can delay approval even where the principal patent ultimately fails.

Weaknesses

• The active ingredient was not new at the time of the litigation.
• Clinical treatment claims face substantial obviousness exposure when prior art discloses the drug, disease, patient population, and titration concepts.
• Commercial success alone did not establish nonobviousness.
• Invalidity eliminated the '405 patent as a post-approval enforcement tool.
• A method patent provides narrower protection than a composition patent.

The case illustrates the risk of relying on late-stage clinical regimen patents to preserve small-molecule exclusivity after primary compound protection has expired.

Which companies were challenging Sensipar exclusivity?

Sandoz was the appellant-level generic challenger in No. 22-1147. Other generic companies may have pursued cinacalcet development or separate ANDA litigation, but this Federal Circuit case addressed Amgen's dispute with Sandoz.

The ruling could have precedential value for other generic applicants if they pursued products with materially similar labeling and relied on the same invalidated patent. It did not automatically resolve separate disputes involving different patents, formulations, dosage strengths, or product labels.

What generic launch risks remained after the decision?

After the Federal Circuit ruling, the principal remaining risks were regulatory and commercial rather than tied to the validity of the '405 patent.

Risk	Impact
Other Orange Book patents	Could support separate litigation or approval delays
FDA review	Could delay or prevent ANDA approval
Bioequivalence	Failure could require additional studies or amendments
Product labeling	A carve-out could affect approval scope
Manufacturing	API sourcing, quality, and supply continuity could affect launch
Settlement	A private agreement could impose a later launch date
Market entry	Multiple generic entrants could sharply reduce price and share
Indication limitations	Narrow labeling could limit commercial uptake

A successful patent challenge does not guarantee immediate launch. Generic companies still must complete FDA review, satisfy manufacturing requirements, establish supply, and assess whether launch economics justify entry.

How did the decision affect Amgen's revenue exposure?

Sensipar revenue was exposed to generic erosion because the product had a mature small-molecule profile and the asserted method patent was invalidated.

The likely commercial consequences were:

• Reduced ability to defer generic competition through the '405 patent.
• Greater probability of price erosion after generic entry.
• Potential loss of dialysis-related cinacalcet volume to ANDA products.
• Increased importance of Amgen's other products and lifecycle programs.
• Lower value for licensing or settlement positions based solely on the '405 patent.

The size and timing of revenue loss depend on the number of approved generics, the timing of launch, payer substitution, channel inventory, and any remaining patents or settlement restrictions. The Federal Circuit ruling materially weakened Amgen's litigation leverage but did not quantify sales loss.

Was there a settlement agreement in Amgen v. Sandoz?

The appellate decision was an affirmance of the district court judgment against Amgen. The reported case does not establish a settlement that replaced the court's invalidity ruling or authorized a negotiated launch date.

Any separate commercial agreement would need to be evaluated independently from the published Federal Circuit opinion. The judicial holding is that the asserted patent could not support the relief Amgen sought against Sandoz.

What is the precedent value of Amgen v. Sandoz?

The decision has three principal implications for pharmaceutical patent strategy:

1. A known drug, known indication, and known patient population can create a strong obviousness challenge to regimen claims.
2. Objective indicia require a nexus to the claimed invention, not merely to the branded product.
3. Method-of-treatment patents can provide meaningful delay but may be less durable than composition, formulation, or manufacturing patents.

The case also reinforces the need for patent portfolios that combine different claim types:

• Composition claims.
• Polymorph and salt claims.
• Formulation claims.
• Dosage-regimen claims.
• Manufacturing-process claims.
• Patient-selection claims.
• Method-of-use claims.

A portfolio concentrated in one treatment-regimen patent is exposed to invalidity and design-around risk.

Key Takeaways

• Amgen Inc. v. Sandoz Inc., No. 22-1147, involved generic cinacalcet, marketed as Sensipar.
• The Federal Circuit affirmed that U.S. Patent No. 9,375,405 was invalid for obviousness.
• The patent covered treatment methods for secondary hyperparathyroidism in dialysis patients.
• Sandoz's Paragraph IV challenge successfully removed the '405 patent as a barrier to its ANDA product.
• The ruling did not itself grant FDA approval or invalidate every Sensipar-related patent.
• The case involved a small-molecule ANDA, not a biosimilar application.
• Amgen's remaining commercial defenses depended on other patents, regulatory status, labeling, manufacturing, and market conditions.
• The decision reduced Amgen's leverage in delaying generic cinacalcet entry and increased revenue-erosion risk.

FAQs About Amgen v. Sandoz No. 22-1147

What drug was at issue in Amgen v. Sandoz?

The drug was cinacalcet hydrochloride, marketed by Amgen as Sensipar. The product is used in specified hyperparathyroidism and related calcium-regulation indications.

Was Amgen's Sensipar patent invalidated or found not infringed?

The Federal Circuit affirmed invalidity based on obviousness. The result was not limited to a finding that Sandoz's product avoided infringement.

Does the decision affect biosimilar litigation?

No. Sensipar is a small-molecule product handled under Hatch-Waxman. The case does not apply the BPCIA procedures used for biosimilars.

Can Sandoz launch generic cinacalcet immediately after the Federal Circuit decision?

The decision removed the asserted '405 patent as a litigation barrier, but launch still depended on FDA approval, other applicable patents, regulatory requirements, and any contractual restrictions.

What should companies monitor after the Amgen v. Sandoz ruling?

Companies should monitor the Orange Book for remaining listings, FDA approval activity for cinacalcet ANDAs, any new patent litigation, product-label carve-outs, generic launch dates, and market-share changes after entry.

References

1. Amgen Inc. v. Sandoz Inc., No. 22-1147, U.S. Court of Appeals for the Federal Circuit (2023).

2. U.S. Food and Drug Administration. (2004). FDA approves Sensipar for hyperparathyroidism in patients with chronic kidney disease on dialysis. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

4. 21 U.S.C. § 355(j) (2023).

5. 35 U.S.C. §§ 103, 271(e), 281 (2023).